The NATRON clinical trial was a 24-week, randomized, double-blind, placebo-controlled, Phase 3 study comparing the efficacy and safety of FASENRA to placebo in patients aged 12 years and older who had signs or symptoms of HES flare or had experienced at least 2 HES flares within the past 12 months.1,2

Blood eosinophil reduction data observed at Week 4* and maintained through Week 241,2

Blood eosinophil counts over a 24-week period†3

Line Graph Showing Blood Eosinophil Counts Over A 24‑Week Period with Separate Plotted Lines for Placebo and a Treatment Group Labeled FASENRA. Line Graph Showing Blood Eosinophil Counts Over A 24‑Week Period with Separate Plotted Lines for Placebo and a Treatment Group Labeled FASENRA.
See study design

FASENRA directly targets eosinophils, a key driver of HES1

The mechanism of action of benralizumab has not been definitively established.

*Week 4 was the first observed timepoint.1

†In patients with HES, reduction of blood eosinophils was consistent with the effect observed in asthma and EGPA trials. Reduction in blood eosinophils was seen at the first observed timepoint (Week 4) and was maintained over the 24-week treatment period.1

EGPA, eosinophilic granulomatosis with polyangiitis; OCS, oral corticosteroid.